Cargando…
Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO r...
Autores principales: | Fiore, Marco, Alfieri, Aniello, Di Franco, Sveva, Pace, Maria Caterina, Simeon, Vittorio, Ingoglia, Giulia, Cortegiani, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400227/ https://www.ncbi.nlm.nih.gov/pubmed/32645986 http://dx.doi.org/10.3390/antibiotics9070388 |
Ejemplares similares
-
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022) -
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017) -
Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021) -
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)